-
Something wrong with this record ?
Endocrine disruptors and other inhibitors of 11β-hydroxysteroid dehydrogenase 1 and 2: Tissue-specific consequences of enzyme inhibition
J. Vitku, L. Starka, M. Bicikova, M. Hill, J. Heracek, L. Sosvorova, R. Hampl,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Grant support
NT12349
MZ0
CEP Register
NT13369
MZ0
CEP Register
- MeSH
- 11-beta-Hydroxysteroid Dehydrogenase Type 1 antagonists & inhibitors metabolism MeSH
- 11-beta-Hydroxysteroid Dehydrogenase Type 2 antagonists & inhibitors metabolism MeSH
- Diabetes Mellitus chemically induced enzymology pathology MeSH
- Endocrine Disruptors pharmacology MeSH
- Glucocorticoids metabolism MeSH
- Enzyme Inhibitors pharmacology MeSH
- Colon drug effects enzymology MeSH
- Humans MeSH
- Metabolic Syndrome chemically induced enzymology pathology MeSH
- Brain drug effects enzymology MeSH
- Neoplasms chemically induced enzymology pathology MeSH
- Obesity chemically induced enzymology pathology MeSH
- Organ Specificity MeSH
- Placenta drug effects enzymology MeSH
- Pregnancy MeSH
- Testis drug effects enzymology MeSH
- Adipose Tissue drug effects enzymology MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
Numerous chemicals in the environment have the ability to interact with the endocrine system. These compounds are called endocrine disruptors (EDs). Exposure to EDs represents one of the hypotheses for decreasing fertility, the increased risk of numerous cancers and obesity, metabolic syndrome and type 2 diabetes. There are various mechanisms of ED action, one of which is their interference in the action of 11β-hydroxysteroid dehydrogenase (11βHSD) that maintains a balance between active and inactive glucocorticoids on the intracellular level. This enzyme has two isoforms and is expressed in various tissues. Inhibition of 11βHSD in various tissues can have different consequences. In the case of EDs, the results of exposure are mainly adverse; on the other hand pharmaceutically developed inhibitors of 11βHSD type 1 are evaluated as an option for treating metabolic syndrome, as well as related diseases and depressive disorders. This review focuses on the effects of 11βHSD inhibitors in the testis, colon, adipose tissue, kidney, brain and placenta.
Charles University 3rd Faculty of Medicine Department of Urology Prague Czech Republic
Faculty Hospital Kralovske Vinohrady Department of Urology Prague Czech Republic
Institute of Endocrinology Department of Steroids and Proteofactors Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16021079
- 003
- CZ-PrNML
- 005
- 20190827135437.0
- 007
- ta
- 008
- 160722s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jsbmb.2014.07.007 $2 doi
- 024 7_
- $a 10.1016/j.jsbmb.2014.07.007 $2 doi
- 035 __
- $a (PubMed)25066675
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vítků, Jana $u Institute of Endocrinology, Department of Steroids and Proteofactors, Prague, Czech Republic. Electronic address: jkubatova@endo.cz. $7 xx0211876
- 245 10
- $a Endocrine disruptors and other inhibitors of 11β-hydroxysteroid dehydrogenase 1 and 2: Tissue-specific consequences of enzyme inhibition / $c J. Vitku, L. Starka, M. Bicikova, M. Hill, J. Heracek, L. Sosvorova, R. Hampl,
- 520 9_
- $a Numerous chemicals in the environment have the ability to interact with the endocrine system. These compounds are called endocrine disruptors (EDs). Exposure to EDs represents one of the hypotheses for decreasing fertility, the increased risk of numerous cancers and obesity, metabolic syndrome and type 2 diabetes. There are various mechanisms of ED action, one of which is their interference in the action of 11β-hydroxysteroid dehydrogenase (11βHSD) that maintains a balance between active and inactive glucocorticoids on the intracellular level. This enzyme has two isoforms and is expressed in various tissues. Inhibition of 11βHSD in various tissues can have different consequences. In the case of EDs, the results of exposure are mainly adverse; on the other hand pharmaceutically developed inhibitors of 11βHSD type 1 are evaluated as an option for treating metabolic syndrome, as well as related diseases and depressive disorders. This review focuses on the effects of 11βHSD inhibitors in the testis, colon, adipose tissue, kidney, brain and placenta.
- 650 _2
- $a 11-beta-hydroxysteroiddehydrogenasa typ 1 $x antagonisté a inhibitory $x metabolismus $7 D043205
- 650 _2
- $a 11-beta-hydroxysteroiddehydrogenasa typ 2 $x antagonisté a inhibitory $x metabolismus $7 D043209
- 650 _2
- $a tuková tkáň $x účinky léků $x enzymologie $7 D000273
- 650 _2
- $a mozek $x účinky léků $x enzymologie $7 D001921
- 650 _2
- $a kolon $x účinky léků $x enzymologie $7 D003106
- 650 _2
- $a diabetes mellitus $x chemicky indukované $x enzymologie $x patologie $7 D003920
- 650 _2
- $a endokrinní disruptory $x farmakologie $7 D052244
- 650 _2
- $a inhibitory enzymů $x farmakologie $7 D004791
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glukokortikoidy $x metabolismus $7 D005938
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metabolický syndrom $x chemicky indukované $x enzymologie $x patologie $7 D024821
- 650 _2
- $a nádory $x chemicky indukované $x enzymologie $x patologie $7 D009369
- 650 _2
- $a obezita $x chemicky indukované $x enzymologie $x patologie $7 D009765
- 650 _2
- $a orgánová specificita $7 D009928
- 650 _2
- $a placenta $x účinky léků $x enzymologie $7 D010920
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a testis $x účinky léků $x enzymologie $7 D013737
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Stárka, Luboslav, $u Institute of Endocrinology, Department of Steroids and Proteofactors, Prague, Czech Republic. $d 1930- $7 jn19990209795
- 700 1_
- $a Bičíková, Marie $u Institute of Endocrinology, Department of Steroids and Proteofactors, Prague, Czech Republic. $7 xx0060369
- 700 1_
- $a Hill, Martin, $u Institute of Endocrinology, Department of Steroids and Proteofactors, Prague, Czech Republic. $d 1962- $7 mzk2005304431
- 700 1_
- $a Heráček, Jiří, $u Charles University, Third Faculty of Medicine, Department of Urology, Prague, Czech Republic; Faculty Hospital Kralovske Vinohrady, Department of Urology, Prague, Czech Republic. $d 1969- $7 nlk20050170272
- 700 1_
- $a Kolátorová Sosvorová, Lucie $u Institute of Endocrinology, Department of Steroids and Proteofactors, Prague, Czech Republic. $7 xx0140729
- 700 1_
- $a Hampl, Richard, $u Institute of Endocrinology, Department of Steroids and Proteofactors, Prague, Czech Republic. $d 1941- $7 jo20000074077
- 773 0_
- $w MED00004950 $t The Journal of steroid biochemistry and molecular biology $x 1879-1220 $g Roč. 155, č. Pt B (2016), s. 207-216
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25066675 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20190827135658 $b ABA008
- 999 __
- $a ok $b bmc $g 1155749 $s 945607
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 155 $c Pt B $d 207-216 $e 20140724 $i 1879-1220 $m Journal of steroid biochemistry and molecular biology $n J Steroid Biochem Mol Biol $x MED00004950
- GRA __
- $a NT12349 $p MZ0
- GRA __
- $a NT13369 $p MZ0
- LZP __
- $a Pubmed-20160722
